---
title: "Guanhao Biotech released its 2024 annual performance, with a net profit attributable to the parent company of 27.4169 million yuan, a year-on-year decrease of 11.57%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237015970.md"
description: "Guanhao Biotech released its 2024 annual performance report, with operating revenue of 377 million yuan, a year-on-year decrease of 6.60%; net profit attributable to the parent company of 27.4169 million yuan, a year-on-year decrease of 11.57%; net profit after deducting non-recurring gains and losses of 19.7143 million yuan, a year-on-year decrease of 35.48%; basic earnings per share of 0.10 yuan/share"
datetime: "2025-04-22T15:59:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237015970.md)
  - [en](https://longbridge.com/en/news/237015970.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237015970.md)
generator: "portal-rs"
---

# Guanhao Biotech released its 2024 annual performance, with a net profit attributable to the parent company of 27.4169 million yuan, a year-on-year decrease of 11.57%

According to the Zhitong Finance APP, Guanhao Biotech (300238.SZ) released its annual report for 2024, reporting an operating income of 377 million yuan for the year, a year-on-year decrease of 6.60%; a net profit attributable to shareholders of the listed company of 27.4169 million yuan, a year-on-year decrease of 11.57%; a net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of 19.7143 million yuan, a year-on-year decrease of 35.48%; and basic earnings per share of 0.10 yuan/share

### Related Stocks

- [300238.CN](https://longbridge.com/en/quote/300238.CN.md)

## Related News & Research

- [Church's Texas Chicken's China debut drew 2-hour lines — and $22 offers to wait in them](https://longbridge.com/en/news/297600833.md)
- [11:25 ETOLAY Expands Its Award-Winning Retinol Collection with New Starter Night Repairing Lotion](https://longbridge.com/en/news/297806392.md)
- [11:00 ETCovationBio's Xatryx® Mass Production On Spec, to Debut First Non‑Food Bio‑Based Athletic Insole at NW Materials Show in the U.S.](https://longbridge.com/en/news/297804526.md)
- [Erste Group 2026 capital, liquidity report shows CET1 ratio 15.24%](https://longbridge.com/en/news/297615907.md)
- [Gentian Diagnostics to attend PReS meeting, spotlight circulating calprotectin testing in pediatric rheumatology](https://longbridge.com/en/news/297638164.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**